| Literature DB >> 21521531 |
David C Muller1, Graham G Giles, Julie Bassett, Howard A Morris, John T Manning, John L Hopper, Dallas R English, Gianluca Severi.
Abstract
BACKGROUND: The second to fourth digit ratio (2D:4D) is used as a marker of prenatal sex hormone exposure. The objective of this study was to examine whether circulating concentrations of sex hormones and SHBG measured in adulthood was associated with 2D:4D.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21521531 PMCID: PMC3107785 DOI: 10.1186/1477-7827-9-57
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 5.211
Demographic and lifestyle factors, and plasma concentrations of hormones and SHBG for the 1036 men
| Characteristic | Category | Values |
|---|---|---|
| Age in years, mean (SD) | 54 (9) | |
| Country of birth, n (%) | Australia/New Zealand/UK/Other | 816 (79) |
| Italy | 129 (12) | |
| Greece | 91 (9) | |
| Smoking, n (%) | Never | 459 (44) |
| Current | 128 (12) | |
| Former | 449 (43) | |
| Alcohol consumption, n (%) | Abstainers | 126 (12) |
| Ex drinkers | 49 (5) | |
| Low | 693 (67) | |
| Medium | 97 (9) | |
| High | 71 (7) | |
| BMI (kg/m2), mean (SD) | 26.9 (3.4) | |
| Right 2D:4D, mean (SD) | Overall | 0.946 (0.036) |
| Australia/New Zealand/UK/Other | 0.948 (0.035) | |
| Italy | 0.938 (0.041) | |
| Greece | 0.941 (0.035) | |
| Left 2D:4D, mean (SD) | Overall | 0.954 (0.035) |
| Australia/New Zealand/UK/Other | 0.955 (0.035) | |
| Italy | 0.949 (0.039) | |
| Greece | 0.955 (0.032) | |
| Δ | Overall | -0.008 (0.033) |
| Australia/New Zealand/UK/Other | -0.007 (0.031) | |
| Italy | -0.011 (0.041) | |
| Greece | -0.014 (0.034) | |
| Total testosterone (nmol/L) | 15.5 (12.3,19.5) | |
| Free testosterone (pmol/L) | 244.1 (189.3,306.1) | |
| Total oestradiol (pmol/L) | 103.0 (87.0,122.0) | |
| Free oestradiol (pmol/L) | 1.7 (1.4,2.0) | |
| DHEAS (μmol/L) | 3.5 (2.3,5.2) | |
| Androstenedione (nmol/L) | 4.1 (3.2,5.4) | |
| Androstenediol glucoronide (ng/mL) | 14.8 (10.3,20.2) | |
| SHBG (nmol/L) | 35.2 (27.0,43.8) | |
| Testosterone:oestradiol ratio | 151.6 (118.5,187.3) | |
1At baseline blood collection. Number of missing measures were 2 for testosterone, 2 for free testosterone,and 66 for androstenediol glucoronide.
Demographic and lifestyle factors, and plasma concentrations of hormones and SHBG for the 620 women
| Characteristic | Category | Values |
|---|---|---|
| Age in years, mean (SD) | 60 (6) | |
| Age at menopause in years, mean (SD) | 50 (4) | |
| Country of birth, n (%) | Australia/New Zealand/UK/Other | 496 (80) |
| Italy | 83 (13) | |
| Greece | 41 (7) | |
| Smoking, n (%) | Never | 446 (72) |
| Current | 42 (7) | |
| Former | 132 (21) | |
| Alcohol consumption, n (%) | Abstainers | 267 (43) |
| Ex drinkers | 16 (3) | |
| Low | 268 (43) | |
| Medium | 57 (9) | |
| High | 12 (2) | |
| Age at menarche, n (%) | <12 | 104 (17) |
| 12 | 126 (20) | |
| 13 | 149 (24) | |
| >= 14 | 241 (39) | |
| Parity, n (%) | Nulliparous | 72 (12) |
| <25 years and 1 pregnancy | 38 (6) | |
| <25 years and >1 pregnancy | 175 (28) | |
| >= 25 years and 1 pregnancy | 169 (27) | |
| >= 25 years and >1 pregnancy | 166 (27) | |
| Duration of lactation, n (%) | never | 156 (25) |
| <= 6 months | 123 (20) | |
| 7-12 months | 104 (17) | |
| 13-24 months | 141 (23) | |
| > 24 months | 96 (15) | |
| Oral Contraceptive use, n (%) | Never | 326 (53) |
| Ex | 294 (47) | |
| HRT use, n (%) | Never | 531 (86) |
| Ex | 89 (14) | |
| BMI (kg/m2), mean (SD) | 27.3 (4.9) | |
| Right 2D:4D, mean (SD) | Overall | 0.953 (0.035) |
| Australia/New Zealand/UK/Other | 0.954 (0.035) | |
| Italy | 0.954 (0.034) | |
| Greece | 0.945 (0.030) | |
| Left 2D:4D, mean (SD) | Overall | 0.961 (0.036) |
| Australia/New Zealand/UK/Other | 0.961 (0.036) | |
| Italy | 0.963 (0.036) | |
| Greece | 0.962 (0.038) | |
| Δ | Overall | -0.008 (0.035) |
| Australia/New Zealand/UK/Other | -0.007 (0.035) | |
| Italy | -0.010 (0.035) | |
| Greece | -0.017 (0.035) | |
| Total testosterone (nmol/L) | 0.7 (0.4,1.1) | |
| Free testosterone (pmol/L) | 7.5 (3.5,12.5) | |
| Total oestradiol (pmol/L) | 57.0 (45.0,73.0) | |
| Free oestradiol (pmol/L) | 0.8 (0.6,1.1) | |
| DHEAS (μmol/L) | 1.5 (0.9,2.5) | |
| Androstenedione (nmol/L) | 2.5 (1.6,3.5) | |
| Oestrone sulphate (ng/mL) | 1.0 (0.7,1.4) | |
| SHBG (nmol/L) | 50.4 (37.7,68.3) | |
| Testosterone:oestradiol ratio | 12.5 (7.8,18.4) | |
1At baseline blood collection. Number of missing measures were 54 for free testosterone and 13 for oestrone sulphate.
Predicted geometric mean (G1) hormone concentration in men by tertiles of right and left 2D:4D and Δ.
| Testosterone (nmol/l) | I | 15.9 | (15.3 - 16.4) | 0.04 | -0.05 | 0.12 | 15.6 | (15.0 - 16.2) | 0.34 | -0.03 | 0.34 | 15.5 | (14.9 - 16.0) | 0.86 | -0.02 | 0.44 |
| II | 15.3 | (14.8 - 15.9) | 15.3 | (14.7 - 15.8) | 15.3 | (14.7 - 15.8) | ||||||||||
| III | 15.0 | (14.5 - 15.6) | 15.2 | (14.7 - 15.8) | 15.4 | (14.9 - 16.0) | ||||||||||
| Free testosterone (pmol/l) | I | 242.1 | (232.1 - 252.0) | 0.07 | -0.04 | 0.19 | 237.4 | (227.7 - 247.2) | 0.50 | -0.02 | 0.51 | 236.6 | (226.8 - 246.4) | 0.81 | -0.03 | 0.42 |
| II | 233.5 | (224.0 - 243.0) | 232.8 | (223.3 - 242.3) | 232.8 | (223.2 - 242.4) | ||||||||||
| III | 229.1 | (219.7 - 238.6) | 232.7 | (223.1 - 242.3) | 234.9 | (225.2 - 244.6) | ||||||||||
| Oestradiol (pmol/l) | I | 104.3 | (99.6 - 108.9) | 0.73 | 0.02 | 0.45 | 104.5 | (99.8 - 109.2) | 0.83 | 0.02 | 0.41 | 104.4 | (99.8 - 109.1) | 0.84 | -0.00 | 0.96 |
| II | 105.6 | (100.9 - 110.3) | 105.3 | (100.6 - 109.9) | 105.7 | (101.0 - 110.5) | ||||||||||
| III | 105.0 | (100.3 - 109.7) | 104.9 | (100.3 - 109.6) | 104.9 | (100.2 - 109.6) | ||||||||||
| Free oestradiol (pmol/l) | I | 1.7 | (1.6 - 1.8) | 0.51 | 0.03 | 0.31 | 1.7 | (1.6 - 1.8) | 0.58 | 0.03 | 0.26 | 1.7 | (1.6 - 1.8) | 0.92 | -0.00 | 0.99 |
| II | 1.7 | (1.7 - 1.8) | 1.7 | (1.6 - 1.8) | 1.7 | (1.7 - 1.8) | ||||||||||
| III | 1.7 | (1.6 - 1.8) | 1.7 | (1.6 - 1.8) | 1.7 | (1.6 - 1.8) | ||||||||||
| DHEAS (μmol/l) | I | 3.3 | (3.1 - 3.5) | 0.37 | -0.03 | 0.28 | 3.4 | (3.2 - 3.6) | 0.07 | -0.04 | 0.13 | 3.3 | (3.1 - 3.5) | 0.68 | 0.01 | 0.64 |
| II | 3.4 | (3.2 - 3.6) | 3.2 | (3.0 - 3.4) | 3.2 | (3.0 - 3.4) | ||||||||||
| III | 3.2 | (3.0 - 3.4) | 3.2 | (3.0 - 3.3) | 3.4 | (3.2 - 3.6) | ||||||||||
| Androstenedione (nmol/l) | I | 4.2 | (3.9 - 4.4) | 0.30 | -0.05 | 0.12 | 4.2 | (4.0 - 4.4) | 0.31 | -0.04 | 0.26 | 4.2 | (4.0 - 4.4) | 0.96 | -0.02 | 0.52 |
| II | 4.2 | (3.9 - 4.4) | 4.2 | (3.9 - 4.4) | 4.0 | (3.8 - 4.2) | ||||||||||
| III | 4.0 | (3.8 - 4.2) | 4.0 | (3.8 - 4.2) | 4.2 | (4.0 - 4.4) | ||||||||||
| Androstenediol glucoronide (ng/ml) | I | 13.9 | (13.0 - 14.8) | 0.11 | 0.05 | 0.11 | 14.0 | (13.2 - 14.9) | 0.32 | 0.03 | 0.32 | 14.2 | (13.3 - 15.1) | 0.49 | 0.02 | 0.57 |
| II | 14.3 | (13.4 - 15.2) | 14.4 | (13.5 - 15.3) | 14.2 | (13.4 - 15.1) | ||||||||||
| III | 14.8 | (13.9 - 15.7) | 14.6 | (13.7 - 15.5) | 14.6 | (13.7 - 15.5) | ||||||||||
| SHHB (nmol/l) | I | 35.0 | (33.6 - 36.3) | 0.50 | -0.02 | 0.57 | 34.7 | (33.4 - 36.0) | 0.60 | -0.02 | 0.60 | 34.5 | (33.2 - 35.8) | 0.98 | -0.01 | 0.82 |
| II | 33.9 | (32.6 - 35.2) | 34.0 | (32.8 - 35.3) | 34.0 | (32.7 - 35.3) | ||||||||||
| III | 34.3 | (33.0 - 35.6) | 34.2 | (33.0 - 35.5) | 34.5 | (33.2 - 35.8) | ||||||||||
1Estimates from linear mixed models of the logarithm of hormone concentration on 2D:4D tertiles with laboratory batch entered as a random intercept, adjusted for ethnicity, age at blood draw, BMI, and smoking status.
2From likelihood ratio test for linear trend across 2D:4D tertiles.
3Standardised regression coefficients (correlations) from linear mixed models of the logarithm of hormone concentration on continuous 2D:4D with laboratory batch entered as a random intercept, adjusted for ethnicity, age at blood draw, BMI, and smoking status.
4From likelihood ratio test of ρ.
Predicted geometric mean (G1) hormone concentration in women by tertiles of right and left 2D:4D and Δ.
| Testosterone (nmol/L) | I | 0.7 | (0.6 - 0.8) | 0.76 | -0.01 | 0.74 | 0.7 | (0.6 - 0.8) | 0.10 | -0.03 | 0.41 | 0.6 | (0.5 - 0.7) | 0.04 | 0.02 | 0.55 |
| II | 0.7 | (0.6 - 0.7) | 0.7 | (0.6 - 0.7) | 0.7 | (0.6 - 0.8) | ||||||||||
| III | 0.7 | (0.6 - 0.7) | 0.6 | (0.5 - 0.7) | 0.7 | (0.6 - 0.8) | ||||||||||
| Free Testosterone (pmol/L) | I | 6.0 | (4.9 - 7.1) | 0.92 | -0.03 | 0.49 | 6.5 | (5.3 - 7.6) | 0.16 | -0.04 | 0.34 | 5.2 | (4.3 - 6.1) | 0.05 | 0.02 | 0.71 |
| II | 6.6 | (5.4 - 7.8) | 6.4 | (5.3 - 7.6) | 6.9 | (5.6 - 8.1) | ||||||||||
| III | 5.9 | (4.9 - 7.0) | 5.6 | (4.6 - 6.5) | 6.5 | (5.3 - 7.6) | ||||||||||
| Oestradiol (pmol/L) | I | 57.0 | (52.1 - 61.9) | 0.50 | 0.02 | 0.63 | 58.0 | (52.9 - 63.0) | 0.77 | 0.02 | 0.64 | 55.1 | (50.3 - 59.9) | 0.62 | -0.00 | 0.91 |
| II | 55.6 | (50.8 - 60.3) | 55.3 | (50.5 - 60.1) | 59.7 | (54.5 - 64.8) | ||||||||||
| III | 58.7 | (53.7 - 63.7) | 57.2 | (52.2 - 62.2) | 56.4 | (51.5 - 61.3) | ||||||||||
| Free oestradiol (pmol/L) | I | 0.8 | (0.7 - 0.9) | 0.85 | -0.00 | 0.89 | 0.8 | (0.7 - 0.9) | 0.64 | 0.00 | 0.95 | 0.8 | (0.7 - 0.8) | 0.73 | -0.01 | 0.73 |
| II | 0.8 | (0.7 - 0.8) | 0.8 | (0.7 - 0.8) | 0.8 | (0.7 - 0.9) | ||||||||||
| III | 0.8 | (0.7 - 0.9) | 0.8 | (0.7 - 0.9) | 0.8 | (0.7 - 0.8) | ||||||||||
| DHEAS (μmol/L) | I | 1.5 | (1.3 - 1.6) | 0.38 | -0.02 | 0.63 | 1.6 | (1.4 - 1.7) | 0.08 | -0.02 | 0.62 | 1.4 | (1.2 - 1.5) | 0.44 | 0.00 | 0.91 |
| II | 1.4 | (1.3 - 1.6) | 1.4 | (1.3 - 1.5) | 1.4 | (1.3 - 1.6) | ||||||||||
| III | 1.4 | (1.2 - 1.5) | 1.4 | (1.2 - 1.5) | 1.5 | (1.3 - 1.6) | ||||||||||
| Androstenedione (nmol/L) | I | 2.4 | (2.2 - 2.6) | 0.26 | -0.04 | 0.40 | 2.4 | (2.2 - 2.7) | 0.16 | -0.05 | 0.27 | 2.2 | (2.0 - 2.4) | 0.10 | 0.01 | 0.77 |
| II | 2.3 | (2.1 - 2.5) | 2.3 | (2.1 - 2.5) | 2.3 | (2.1 - 2.5) | ||||||||||
| III | 2.2 | (2.1 - 2.4) | 2.3 | (2.1 - 2.4) | 2.4 | (2.2 - 2.6) | ||||||||||
| Oestrone sulphate (ng/mL) | I | 1.1 | (1.0 - 1.2) | 0.68 | -0.03 | 0.44 | 1.1 | (1.0 - 1.2) | 0.35 | -0.01 | 0.85 | 1.0 | (0.9 - 1.1) | 0.51 | -0.01 | 0.72 |
| II | 1.0 | (0.9 - 1.1) | 1.0 | (0.9 - 1.1) | 1.0 | (0.9 - 1.1) | ||||||||||
| III | 1.0 | (1.0 - 1.1) | 1.0 | (0.9 - 1.1) | 1.1 | (1.0 - 1.1) | ||||||||||
| SHGB (nmol/L) | I | 48.3 | (45.3 - 51.3) | 0.26 | 0.06 | 0.13 | 49.5 | (46.4 - 52.6) | 0.74 | 0.04 | 0.26 | 50.0 | (46.8 - 53.1) | 0.65 | 0.02 | 0.66 |
| II | 50.8 | (47.7 - 54.0) | 50.0 | (46.9 - 53.0) | 48.6 | (45.6 - 51.6) | ||||||||||
| III | 50.6 | (47.5 - 53.8) | 50.2 | (47.1 - 53.3) | 50.9 | (47.8 - 54.1) | ||||||||||
1Estimates from linear mixed models of the logarithm of hormone concentration on 2D:4D tertiles with laboratory batch entered as a random intercept, adjusted for ethnicity, age at blood draw, BMI, smoking status, previous oral contraceptive and HRT use, parity, duration of lactation, and age at menarche.
2From likelihood ratio test for linear trend across 2D:4D tertiles.
3Standardised regression coefficients (correlations) from linear mixed models of the logarithm of hormone concentration on continuous 2D:4D with laboratory batch entered as a random intercept, adjusted for ethnicity, age at blood draw, BMI, smoking status, previous oral contraceptive and HRT use, parity, duration of lactation, and age at menarche.
4From likelihood ratio test of ρ.
Predicted mean1 relative concentrations of testosterone and oestradiol in men by tertiles of right and left 2D:4D and Δ.
| Testosterone:oestradiol | I | 160.2 | (152.6 - 167.9) | 0.03 | -0.06 | 0.03 | 158.9 | (151.3 - 166.5) | 0.19 | -0.05 | 0.07 | 155.7 | (148.1 - 163.4) | 0.82 | -0.01 | 0.69 |
| II | 154.1 | (146.5 - 161.8) | 153.4 | (145.9 - 160.9) | 154.0 | (146.4 - 161.7) | ||||||||||
| III | 152.1 | (144.5 - 159.8) | 154.2 | (146.6 - 161.7) | 156.5 | (148.9 - 164.2) | ||||||||||
| Free testosterone:free oestradiol | I | 157.0 | (148.6 - 165.4) | 0.02 | -0.07 | 0.02 | 155.4 | (147.1 - 163.8) | 0.11 | -0.06 | 0.04 | 151.1 | (142.6 - 159.5) | 0.92 | -0.01 | 0.64 |
| II | 148.5 | (140.1 - 156.9) | 147.4 | (139.0 - 155.7) | 148.3 | (139.9 - 156.8) | ||||||||||
| III | 146.2 | (137.8 - 154.6) | 148.1 | (139.7 - 156.4) | 151.5 | (143.0 - 160.0) | ||||||||||
1Estimates from linear mixed models of the ratio of hormone concentrations on 2D:4D tertiles with laboratory batch entered as a random intercept, adjusted for ethnicity, age at blood draw, BMI, and smoking status.
2From likelihood ratio test for linear trend across 2D:4D tertiles.
3Standardised regression coefficients (correlations) from linear mixed models of the logarithm of hormone concentration on continuous 2D:4D with laboratory batch entered as a random intercept, adjusted for ethnicity, age at blood draw, BMI, and smoking status.
4From likelihood ratio test of ρ.
Predicted mean1 relative concentrations of testosterone and oestradiol in women by tertiles of right and left 2D:4D and Δ.
| Testosterone:oestradiol | I | 15.0 | (13.0 - 16.9) | 0.39 | -0.03 | 0.38 | 14.6 | (12.6 - 16.5) | 0.56 | -0.03 | 0.52 | 14.0 | (12.1 - 16.0) | 0.24 | -0.00 | 0.98 |
| II | 14.7 | (12.8 - 16.6) | 15.4 | (13.4 - 17.3) | 14.6 | (12.6 - 16.5) | ||||||||||
| III | 14.2 | (12.3 - 16.1) | 14.0 | (12.1 - 16.0) | 15.1 | (13.2 - 17.1) | ||||||||||
| Free testosterone:free oestradiol | I | 11.4 | (9.6 - 13.3) | 0.58 | -0.04 | 0.32 | 11.2 | (9.4 - 13.0) | 0.68 | -0.02 | 0.60 | 10.7 | (8.8 - 12.5) | 0.31 | -0.01 | 0.83 |
| II | 11.6 | (9.7 - 13.4) | 11.9 | (10.1 - 13.7) | 11.4 | (9.6 - 13.3) | ||||||||||
| III | 10.9 | (9.1 - 12.7) | 10.8 | (9.0 - 12.6) | 11.7 | (9.8 - 13.5) | ||||||||||
1Estimates from linear mixed models of the ratio of hormone concentrations on 2D:4D tertiles with laboratory batch entered as a random intercept, adjusted for ethnicity, age at blood draw, BMI, smoking status, previous oral contraceptive and HRT use, parity, duration of lactation, and age at menarche.
2From likelihood ratio test for linear trend across 2D:4D tertiles.
3Standardised regression coefficients (correlations) from linear mixed models of the logarithm of hormone concentration on continuous 2D:4D with laboratory batch entered as a random intercept, adjusted for ethnicity, age at blood draw, BMI, smoking status, previous oral contraceptive and HRT use, parity, duration of lactation, and age at menarche.
4From likelihood ratio test of ρ.